Since LMP1 has been demonstrated to increase drug resistance in lymphoma cells [20], LMP1-driven constitutive NF-κB activation, in cooperation with the multifunctional effect of LMP1 on diverse signaling pathways, may be responsible for the poorer prognosis of EBV+ DLBCL. Here, PDLIM7 is linked to lymphoma.